Vaccines - Ukraine | Statista Market Forecast

In Ukraine, the Vaccines market is expected to achieve a revenue of US$150.10m by 2024.
It is projected to experience an annual growth rate (CAGR 2024-2029) of -9.51%, leading to a market volume of US$91.06m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$29.12bn in 2024.
Ukraine's vaccine market is witnessing a surge in demand due to increasing awareness and government initiatives.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Vaccines against infectious diseases
Prophylactic and therapeutic vaccines
Flu vaccines
COVID-19 vaccines

Sera and gammaglobulins
Antivirals
Antibiotics

The demand for vaccines in Ukraine has been on the rise in recent years due to various reasons.

Customer preferences: Ukrainians have become more health-conscious and are now more willing to invest in their health. The COVID-19 pandemic has also played a significant role in increasing the demand for vaccines. People are now more aware of the importance of vaccines in preventing diseases and are willing to take them.

Trends in the market: The vaccines market in Ukraine has been growing steadily in recent years. The government has been investing heavily in the healthcare sector, which has led to the development of better healthcare facilities and an increase in the availability of vaccines. The private sector has also been playing a significant role in the market, with many companies investing in research and development of new vaccines.

Local special circumstances: Ukraine has been facing several health challenges in recent years, including a high incidence of infectious diseases such as measles, hepatitis, and tuberculosis. The government has been working to address these challenges by investing in the healthcare sector and increasing the availability of vaccines. The conflict in eastern Ukraine has also led to an increase in the demand for vaccines, as people are more vulnerable to diseases in conflict zones.

Underlying macroeconomic factors: The Ukrainian economy has been growing steadily in recent years, which has led to an increase in the disposable income of the population. This has made it easier for people to invest in their health and has led to an increase in the demand for vaccines. The government's efforts to improve the healthcare sector have also had a positive impact on the market. However, the market still faces several challenges, including a lack of access to vaccines in rural areas and a lack of awareness about the importance of vaccines.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.